fda compounding glp-1 warning letters september 2025 Letter Breakdown: Sterility Failures, Subpotent Drugs, and a Pharmacy Operating Without Control U.S. Food & Drug Administration

While these providers still account for less than 20% of overall GLP-1 volume, their adoption signals a major shift in how these powerful drugs are perceived as the prescribing audience expands

As the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) expands, so too does our knowledge of just what all these medications can do

Describes general patterns observed in published research on the individual ingredients, not specific product claims

These include additional focus on social determinants of health, the healthcare system and physical activity behaviours including sleep

Ozempic and other GLP-1 receptor agonists can increase insulin secretion, suppress glucagon release, slow digestion, and more

Helps maintain GLP-1 results*